Limited uptake of hepatitis C treatment among injection drug users
about
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysisHepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factorsBarriers to hepatitis C treatmentHepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and preventionTreat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV CoinfectionFactors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC StudyDrug Authorization for Sofosbuvir/Ledipasvir (Harvoni) for Chronic HCV Infection in a Real-World Cohort: A New Barrier in the HCV Care CascadeCost-effectiveness of HCV case-finding for people who inject drugs via dried blood spot testing in specialist addiction services and prisonsPrevention of hepatitis C virus in injecting drug users: a narrow window of opportunityInfectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver.Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.Hepatitis C treatment experiences and decision making among patients living with HIV infection.Paying for prevention: challenges to health insurance coverage for biomedical HIV prevention in the United States.Factors that influence an HIV coinfected patient's decision to start hepatitis C treatmentAccess to healthcare insurance and healthcare services among syringe exchange program clients in Massachusetts: qualitative findings from health navigators with the iDU ("I do") Care Collaborative.The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study.Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmissionMedical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.Ending hepatitis C in the United States: the role of screening.Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirinFeasibility of providing interventions for injection drug users in pharmacy settings: a case study among San Francisco pharmacistsIdentification of substance use and dependence among patients with viral hepatitis.Awareness of biologically confirmed HCV among a community residing sample of drug users in Baltimore City.Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.Portraying persons who inject drugs recently infected with hepatitis C accessing antiviral treatment: a cluster analysis.Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.Changes in blood-borne infection risk among injection drug users.Predictors and effects of alcohol use on liver function among young HCV-infected injection drug users in a behavioral intervention.Hepatitis C virus infection is not an independent risk factor for obstructive lung disease.Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence researchChallenges facing providers caring for HIV/HCV-coinfected patientsRelationship between hepatitis C clinical testing site and linkage to careCommunity-based HCV screening: knowledge and attitudes in a high risk urban populationBarriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidenceThe cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.
P2860
Q26822903-F04F4B41-1565-4155-827E-A61FD5AC1175Q26853671-3C94C498-5938-4F87-AFFC-F599927C009AQ27012664-93E01FCA-F042-488E-BA48-049237C47BB6Q27014761-8D3C28A0-60CA-4770-974A-CCA73C109D30Q27491016-FBCC24E5-4DFC-4128-8A22-812AD36B3B09Q27491349-52FC25A9-A634-456A-99EA-94E36DD605F9Q28547529-8EE72518-C87E-4714-8FC5-5F4455D18BE2Q28681550-11DC1AC0-623F-40C2-9E27-1C6A131326F4Q28741305-7F7873DB-505D-4F7F-B31D-10FB84A446F1Q30395708-457769EE-469C-4E89-B10A-40DCC7384D3CQ30405780-1C9B6467-B75B-457C-9D88-292192D6AF88Q30429470-3FE1AF42-54C1-4580-8FF8-3F8F65E2BA55Q30453975-6D855EF1-5E1F-4A16-BA7D-43E8C432C675Q33391761-D8EBC1D2-2101-4BE1-8156-8AEF0F20CC3FQ33636377-C25379B7-EFCC-4FFE-9E53-67E8543481ACQ33696533-F646BA95-F2A1-4938-8988-00E971899DB4Q33705645-83F99A27-77F0-4BED-A8B6-D433A5002F8FQ33706376-6672B20F-BA73-46AC-886A-EF24B54328CCQ33726091-ADE68F04-4E98-4A2F-B49E-AAB229972A68Q33802414-C31AC010-F160-4AB6-9C4B-EDAACAB998CEQ33825807-56FC2016-D390-425F-94A8-22F5952F4B69Q33853664-B68B64CF-6192-4207-A2BF-55B92C009F09Q33862919-C6AD1414-2DB6-40EC-A2F2-D8C75B28BAA9Q33936783-C63AD43F-8027-4644-883C-B9B8F4A70200Q33956101-B60DFD5F-D578-4ACB-924E-767332A86993Q34023364-88AEDDCF-CF8C-41D2-BE28-F7709217E47CQ34077806-A54A8AF3-4492-4C7D-A9DC-E0B3EDDFB59AQ34260584-6A8DBABC-9464-4333-AAC2-E67E58D40510Q34332039-E362B2FC-3A1E-40A9-998F-FDB98B3CD5BDQ34348710-135B1613-5014-440B-A2A0-B3BF6AE739A3Q34417838-34227F6C-337E-4E68-AC74-1494F4A7C691Q34772870-7941C147-63FD-4AE6-912B-83912216DBCFQ34981603-B6237DAA-D4E2-47B8-BCA9-3872DBC14450Q34998846-C57B3A1E-04A2-4B44-AEC4-25665718988AQ35008754-74CC23EA-35DE-497C-A6E5-D9B231BA70F0Q35068905-94276820-6A43-4C80-A815-C141F3AB2C7CQ35071918-9BE74081-914F-4B3F-A160-74633E680C7CQ35089934-1B0EDB60-CC35-4A90-B94C-F0547F73338AQ35540200-665C5634-87CC-4EEC-8C22-91919146CC87Q35572125-77790B4D-FF90-41C8-8806-48C6EE14ADFE
P2860
Limited uptake of hepatitis C treatment among injection drug users
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Limited uptake of hepatitis C treatment among injection drug users
@en
Limited uptake of hepatitis C treatment among injection drug users.
@nl
type
label
Limited uptake of hepatitis C treatment among injection drug users
@en
Limited uptake of hepatitis C treatment among injection drug users.
@nl
prefLabel
Limited uptake of hepatitis C treatment among injection drug users
@en
Limited uptake of hepatitis C treatment among injection drug users.
@nl
P2093
P2860
P50
P1476
Limited uptake of hepatitis C treatment among injection drug users
@en
P2093
David L Thomas
Gregory D Kirk
Jacquie Astemborski
Ravi Kavasery
Shruti H Mehta
P2860
P2888
P304
P356
10.1007/S10900-007-9083-3
P577
2008-06-01T00:00:00Z